Who are Dexamethasone, steroid; oral or intravenous's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Zurzuvae, Ztalmy, Kerendia, Zulresso, Emflaza, Fluocinolone Acetonide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dexamethasone-steroid-oral-or-intravenous.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Dexamethasone, steroid; oral or intravenous — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dexamethasone, steroid; oral or intravenous (Dexamethasone, steroid; oral or intravenous) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: steroid. Area: Immunology.

phase 2 steroid Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Dexamethasone, steroid; oral or intravenous (Dexamethasone, steroid; oral or intravenous) — Pfizer. Dexamethasone is a synthetic corticosteroid that functions as a potent anti-inflammatory agent by inhibiting the production of pro-inflammatory cytokines and mediators.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Dexamethasone, steroid; oral or intravenous TARGET	Dexamethasone, steroid; oral or intravenous	Pfizer	phase 2	steroid
Zurzuvae	ZURANOLONE	Biogen	marketed	Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator [EPC]	GABA A receptor alpha-4/beta-3/delta	2023-01-01
Ztalmy	GANAXOLONE	Marinus	marketed	Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator [EPC]	GABA A receptor alpha-2/beta-1/gamma-2	2022-01-01
Kerendia	FINERENONE	Bayer	marketed	Nonsteroidal Mineralocorticoid-Receptor Antagonist [EPC]	Mineralocorticoid receptor	2021-01-01
Zulresso	BREXANOLONE	Sage Therap	marketed	Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator	GABA-A receptor alpha-1/beta-2/gamma-2	2019-01-01
Emflaza	DEFLAZACORT	Ptc Therap	marketed	Corticosteroid [EPC]		2017-01-01
Fluocinolone Acetonide	FLUOCINOLONE	Eurofarma	marketed	Corticosteroid [EPC]		2016-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (steroid class)

EMS · 1 drug in this class
Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dexamethasone, steroid; oral or intravenous — Competitive Intelligence Brief. https://druglandscape.com/ci/dexamethasone-steroid-oral-or-intravenous. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab